Overview

Cetuximab/Paclitaxel/Cisplatin Concurrent Chemoradiotherapy Followed by Esophagectomy for Loco-regional Esophageal Cancer

Status:
Unknown status

Trial end date:
2012-06-01

Target enrollment:

Participant gender:

Summary

We hypothesize that the addition of cetuximab to twice weekly paclitaxel/cisplatin concurrent chemoradiotherapy (TP-CCRT) as the adjunctive therapy before esophagectomy or as a definitive CRT would improve the therapeutic efficacy of TP-CCRT in patients with loco-regional esophageal squamous cell carcinoma (ESCC).

Phase:

Phase 2

Details

Lead Sponsor:

National Taiwan University Hospital

Treatments:

Albumin-Bound Paclitaxel
Cetuximab
Cisplatin
Paclitaxel